SCHEMBL19084974

SCHEMBL19084974

COc1ccc(-c2ccccc2F)c(OC)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A1 P04798 3/20 0.56
▸ CYP1B1 Q16678 3/20 0.56
▸ CYP1A2 P05177 2/20 0.56
▸ CYP2E1 P05181 1/20 0.56
▸ CYP3A4 P08684 1/20 0.56
▸ CYP2C8 P10632 1/20 0.56
▸ CYP2D6 P10635 1/20 0.56
▸ CYP2A6 P11509 1/20 0.56
▸ CYP2C9 P11712 1/20 0.56
▸ CYP4B1 P13584 1/20 0.56
▸ CYP2B6 P20813 1/20 0.56
▸ CYP3A5 P20815 1/20 0.56
▸ CYP2A7 P20853 1/20 0.56
▸ CYP3A7 P24462 1/20 0.56
▸ CYP2F1 P24903 1/20 0.56
▸ CYP2C18 P33260 1/20 0.56
▸ CYP2C19 P33261 1/20 0.56
▸ CYP2J2 P51589 1/20 0.56
▸ CYP4F2 P78329 1/20 0.56
▸ CYP4F8 P98187 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22537008 0.87 NPC1 (0.55) CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4
SCHEMBL28588853 0.86 HDAC4 (0.58) CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4
SCHEMBL9272421 0.85 CYP1A2 (0.63) CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4
SCHEMBL28327203 0.83 RAB9A (0.57) CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4
SCHEMBL18339168 0.83 ERN1 (0.47) CYP1A1CYP1B1CYP1A2MAPTNPC1
SCHEMBL29589241 0.82 CYP1A1 (0.69) CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4
SCHEMBL196689 0.82 CYP1A1 (0.69) CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4
SCHEMBL4970050 0.82 HDAC4 (0.50) CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4
SCHEMBL19077651 0.82 ACHE (0.48) CYP1A2CYP3A4CYP2C9CYP2C19MAPT
SCHEMBL30012355 0.81 ERN1 (0.46) CYP1A1CYP1B1CYP1A2MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220109115-A1 POLYCYCLIC COMPOUND, AND AN ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING THE POLYCYCLIC COMPOUND IDEMITSU KOSAN CO.,LTD. (JP) 2022-04-07 — — US disclosed
CN-113394349-A Heterocyclic compound, light-emitting element, light-emitting device, electronic device, and lighting device 株式会社半导体能源研究所 2021-09-14 — — CN disclosed
CN-106279196-B Heterocyclic compound, light-emitting element, light-emitting device, electronic device, and lighting device 株式会社半导体能源研究所 2021-06-29 — — CN disclosed
WO-2020044270-A1 POLYCYCLIC COMPOUND, AND AN ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING THE POLYCYCLIC COMPOUND IDEMITSU KOSAN CO., LTD. (JP) 2020-03-05 — — WO disclosed
WO-2018116152-A1 SPECIFICALLY SUBSTITUTED LADDER TYPE COMPOUNDS FOR ORGANIC LIGHT EMITTING DEVICES IDEMITSU KOSAN CO., LTD. (JP) 2018-06-28 — — WO disclosed
US-20170194573-A1 CONDENSED CYCLIC COMPOUND AND AN ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2017-07-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170194573-A1 CONDENSED CYCLIC COMPOUND AND AN ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME CRY1, CRY2, CCNT1 CYP1A1 184/4885CYP1B1 260/4885CYP1A2 659/4885
US-20220109115-A1 POLYCYCLIC COMPOUND, AND AN ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING THE POLYCYCLIC COMPOUND ODC1, OTC, PKD1 CYP1A1 357/4885CYP1B1 504/4885CYP1A2 422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback